LLY vs PG: Which Is the Better Buy?
Side-by-side comparison of Eli Lilly and Company and The Procter & Gamble Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-17.
Eli Lilly and Company · Healthcare
$1,179.09
+31.7% upside to fair value
High Conviction
Grade A
High Quality
VS
The Procter & Gamble Company · Consumer Defensive
$150.38
+10.0% upside to fair value
Grade B
High Quality
QuantHub Verdict
LLY has more upside to fair value
(+31.7%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
LLY |
PG |
| Current Price |
$1,179.09 |
$150.38 |
| Fair Value Estimate |
$1,552.32 |
$165.39 |
| Upside to Fair Value |
+31.7%
|
+10.0%
|
| Market Cap |
$1,110.4B |
$350.2B |
| Forward P/E |
—
|
21.5x
|
| EV / EBITDA |
34.3x
|
15.1x
|
| Price / Sales |
14.6x
|
4.0x
|
| Price / FCF |
77.7x
|
23.3x
|
| Revenue Growth YoY |
+55.5%
|
+7.4%
|
| Gross Margin |
83.5%
|
50.3%
|
| Operating Margin |
45.9%
|
23.2%
|
| Return on Equity |
101.3%
|
31.3%
|
| Dividend Yield |
0.55% |
0% |
| FCF Yield |
1.29%
|
4.29%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
Eli Lilly is a global biopharma company whose exceptionally profitable cardiometabolic franchises, led by Mounjaro and Zepbound, are driving a high-quality growth phase: revenue rose 55.5% year over year and earnings rose 168.0% year over year in the most recent quarter, while gross, operating, and net margins were 83.5%, 45.9%, and 35.0%, respectively. Business quality is high because tirzepatid…
The Procter & Gamble Company is a leading global consumer defensive company specializing in household and personal products with a strong portfolio across fabric care, baby and family care, beauty, health care, and grooming. The business quality is high, supported by a durable competitive moat from strong brands, consistent earnings growth, and prudent capital allocation emphasizing dividends and…
Accumulation Zones
| Metric |
LLY |
PG |
| Zone Low |
$1,164.24 |
$124.04 |
| Zone High |
$1,319.47 |
$140.58 |
| In Buy Zone? |
Yes
|
No
|